New hope for Men's bones: prolia study targets osteoporosis in china

NCT ID NCT06332014

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the drug Prolia works for men with osteoporosis in mainland China. About 102 men aged 30 to 90 with weak bones will receive Prolia injections. The main goal is to see if bone density in the lower spine improves after 12 months of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS

Contacts and locations

Locations

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, 100035, China
Huaian First Peoples Hospital

Huaian, Jiangsu, 223300, China
Jiangxi Provincial Peoples Hospital

Nanchang, Jiangxi, 330038, China
Nanfang Hospital Southern Medical University

Guangzhou, Guangdong, 510515, China
Peking University First Hospital

Beijing, Beijing Municipality, 100034, China
Pingxiang Peoples Hospital

Pingxiang, Jiangxi, 337000, China
Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China
Shanghai Sixth Peoples Hospital

Shanghai, 200233, China
Sun Yat-sen Memorial Hospital Sun Yat-sen University

Guangzhou, Guangdong, 510120, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221002, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400042, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Peoples Hospital of Kunshan

Suzhou, Jiangsu, 215300, China
The Fourth Hospital of Harbin Medical University

Harbin, Heilongjiang, 150001, China
The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210011, China
Xuzhou Central Hospital

Xuzhou, Jiangsu, 221009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.